Clinical TrialsSearch results
Number of results: 853
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Recruiting
- A Phase 2/3, Open-label, Historical-controlled, Single-arm, Multicenter Studyto Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety ofRavulizumab in Children and Adolescents With Aquaporin-4 Antibody Positive(AQP4-Ab [+]) Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Neuromyelitis Optica Spectrum Disorder
- Wuebbenhorst Hiroaki
- 2022-08-09
Recruiting
- A Phase 3 study of S-217622 targeting non-hospitalized participants
- COVID-19
- Portsmouth Simon
- 2022-10-01
Recruiting
- A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD
- Atopic Dermatitis
- Jain Neal
- 2023-07-01
Recruiting
- A Phase 3, Open-label Study Assessing Self-administered Rocatinlimab (AMG 451) in Subjects With Moderate-to-severe AD
- Atopic Dermatitis
- Chen Sarah
- 2024-04-23
Recruiting
- A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in warm autoimmune hemolytic anemia (wAIHA) patients who failed at least one line of treatment.
- Warm Autoimmune Hemolytic Anemia
- Yamauchi Kyosuke
- 2023-02-01
Recruiting
- A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors (eNRGy)
- NSCLC, pancreatic adenocarcinoma and all other solid tumors with NRG1 fusion
- Wasserman Ernesto
- 2021-12-14
Recruiting
- A phase II/III study of NPC-22
- chronic sialorrhea
- Miyoshi Katsunori
- 2024-06-14
Recruiting
- A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer
- Breast Cancer
- Inoguchi Akihiro
- 2024-03-20
Recruiting
- A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)
- NSCLC
- Hibi Kazushige
- 2023-02-06
Recruiting
- A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-Center Study to Evaluate the Efficacy and Safety of nemolizumab in Japanese Infant and Pediatric Atopic Dermatitis Patients with moderate to severe pruritus
- Pruritus of atopic dermatitis which is inadequately controlled by the currently available therapy
- Nishiura Tomoyuki
- 2023-06-25